Chronic Obstructive Pulmonary Disease

Drug candidate leads to improved endurance

An international group of scientists has shown that a drug candidate designed by scientists from the Florida campus of The Scripps Research Institute (TSRI) significantly increases exercise endurance in animal models.

Jul 14, 2013
popularity 5 / 5 (7) | comments 0 | with audio podcast

AstraZeneca in $560 m deal for respiratory firm

British drugmaker AstraZeneca PLC says it is to acquire Pearl Therapeutics Inc., a Redwood-City, California-based company involved in therapies for asthma and chronic obstructive pulmonary disease for at least $560 million.

Jun 10, 2013
popularity not rated yet | comments 0

Latest Spotlight News